Piper Sandler analyst David Amsellem upgraded Intra-Cellular to Overweight from Neutral with a price target of $92, up from $68.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITCI:
- Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences
- Intra-Cellular price target raised to $81 from $79 at JPMorgan
- Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference
- Intra-Cellular price target raised to $130 from $120 at Cantor Fitzgerald
- Intra-Cellular price target lowered to $74 from $77 at Goldman Sachs